4-Aryl-1,2,3-triazole: A Novel Template for a Reversible Methionine Aminopeptidase 2 Inhibitor, Optimized To Inhibit Angiogenesis in Vivo
Kallander, L.S., Lu, Q., Chen, W., Tomaszek, T., Yang, G., Tew, D., Meek, T.D., Hofmann, G.A., Schulz-Pritchard, C.K., Smith, W.W., Janson, C.A., Ryan, M.D., Zhang, G.F., Johanson, K.O., Kirkpatrick, R.B., Ho, T.F., Fisher, P.W., Mattern, M.R., Johnson, R.K., Hansbury, M.J., Winkler, J.D., Ward, K.W., Veber, D.F., Thompson, S.K.(2005) J Med Chem 48: 5644-5647
- PubMed: 16134930
- DOI: https://doi.org/10.1021/jm050408c
- Primary Citation of Related Structures:
2ADU - PubMed Abstract:
Inhibitors of human methionine aminopeptidase type 2 (hMetAP2) are of interest as potential treatments for cancer. A new class of small molecule reversible inhibitors of hMetAP2 was discovered and optimized, the 4-aryl-1,2,3-triazoles. Compound 24, a potent inhibitor of cobalt-activated hMetAP2, also inhibits human and mouse endothelial cell growth. Using a mouse matrigel model, this reversible hMetAP2 inhibitor was also shown to inhibit angiogenesis in vivo.
Organizational Affiliation:
GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA. lara.s.kallander@gsk.com